Dianthus Therapeutics | MGTA - Operating Expenses


Dianthus Therapeutics reported $40.68M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Alaunos Therapeutics USD 1.19M 428K Sep/2025
Avita Medical AUD 29.57M 1.21M Jun/2025
Celltrion KRW 724.99B 6B Sep/2025
Cspc Pharmaceutical CNY 5.4B 298.41M Sep/2025
Dianthus Therapeutics USD 40.68M 5.56M Sep/2025
Divis Laboratories Ltd INR 19.4B 1.47B Sep/2025
IQVIA Holdings USD 6.16B 2.7B Sep/2025
Kangmei Pharma CNY 1.39B 144.29M Sep/2025
Knight Therapeutics CAD 89.06M 2.02M Sep/2024
Laboratorios Farma EUR 313.62M 17.98M Dec/2023
Malin Corporation EUR 1.1M 400K Dec/2024
Medical Developments International AUD 10.02M 9.78M Jun/2025
Moderna USD 1.28B 232M Sep/2025
Neuren Pharmaceuticals AUD 8.69M 8.72M Jun/2025
Organigram Holdings CAD 108.11M 17.03M Sep/2025
Organon & Co USD 906M 362M Sep/2025
Pharma Mar EUR 39.62M 7.34M Sep/2025
Qiagen NV USD 395.29M 2.28M Sep/2025
Revvity USD 600.61M 12.7M Sep/2025
Sartorius EUR 693.1M 29.4M Sep/2025
Sino Biopharmaceutical CNY 12.39B 1.26B Jun/2025
Tectonic Therapeutic USD 21.89M 440K Sep/2025
Tilray USD 237.52M 17.34M Sep/2025
Viatris USD 3.53B 128.7M Sep/2025
Xeris Pharmaceuticals USD 67.65M 590K Sep/2025
Zz Pientze Pharmaceu CNY 1.55B 129.66M Sep/2025